Oscient reiterated by JMP

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a market outperform rating on news that Factive total prescriptions for the week ended Jan. 13 were 6,944 (6,705 of which were new prescriptions), representing 0.93% of weekly prescriptions for the quinolone class of antibiotics, compared to 7,186 total prescriptions (6,965 of which were new) in the previous week. Total Testim scripts for the week ended Jan. 13 were 4,852, compared with 4,707 for the previous week. Shares of the Waltham, Mass., pharmaceutical company were down 24 cents, or 10.62%, at $2.02 on volume of 1,866,813 shares versus the three-month running average of 506,830 shares. (Nasdaq: OSCI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.